AI research biotech Earendil Labs has penned a $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates.
- Home |
- Earendil pens $885M pact to use WuXi XDC’s linker tech for next-gen ADCs
Earendil pens $885M pact to use WuXi XDC’s linker tech for next-gen ADCs
- February 27, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
